

PROGRAMME

CONSENSUS WORKSHOP PERSONALIZED CARE IN PORTAL HYPERTENSION




October 27-30, 2021

PEDIATRIC RESEARCH WORKSHOP

Primary Prophylaxis of Variceal Hemorrhage, Complexities in the Development of Evidence-Based Approaches in Pediatrics

October 31, 2021



BAVENO COOPERATION STEERING COMMITTEE

HONORARY PRESIDENT

October 27-30, 2021

Roberto de Franchis, Milan (Italy)

CHAIR

Jaime Bosch, Bern (Switzerland)

VICE-CHAIR

Guadalupe Garcia-Tsao, New Haven (USA)

Juan G. Abraldes, Edmonton (Canada)

Agustin Albillos, Madrid (Spain)

Annalisa Berzigotti, Bern (Switzerland)

Gennaro D'Amico, Palermo (Italy)

Andrea De Gottardi, Lugano (Switzerland)

Alessandra Dell'Era. Milan (Italy)

Juan Carlos Garcia-Pagàn, Barcelona (Spain)

Joan Genescà, Barcelona (Spain)

Aleksander Krag, Odense (Denmark)

Wim Laleman, Leuven (Belgium)

Vincenzo La Mura, Milan (Italy)

Dominique Thabut, Paris (France)

Jonel Trebicka, Frankfurt (Germany)

Emmanouil Tsochatzis, London (UK)

Dominique Valla, Paris (France)

Candid Villanueva, Barcelona (Spain)

SCIENTIFIC SECRETARIES

Thomas Reiberger, Vienna (Austria) Cristina Ripoll, Jena (Germany) October 27-30, 2021



The Baveno Cooperation is an official EASL Research Consortium

SUPPORTED BY























ENDORSED BY





Bavenotic Consensus Workshop Personalized care in Portal Hypertension October 27-30, 2021 FACULTY

Juan G. Abraldes - Edmonton, Canada **Agustin Albillos** - Madrid, Spain Anna Baiges - Barcelona, Spain Jasmohan Bajaj - Richmond, USA Rafael Bañares - Madrid, Spain Marta Barrufet - Barcelona, Spain Annalisa Berzigotti - Bern, Switzerland Jaime Bosch - Bern, Switzerland Christophe Bureau - Toulouse, France Vincenza Calvaruso - Palermo, Italy Andrés Càrdenas - Barcelona, Spain Gennaro D'Amico - Palermo, Italy Roberto de Franchis - Milan, Italy Andrea De Gottardi - Lugano, Switzerland Alessandra Dell'Era - Milan, Italy Angels Escorsell - Barcelona, Spain Jonathan Fallowfield - Edinburgh, United Kingdom Hector Ferral - Evanston, USA Sven Francque - Antwerp, Belgium Ron Gaba - Chicago, USA Juan Carlos Garcia Pagàn - Barcelona, Spain Guadalupe Garcia-Tsao - New Haven, USA Joan Genescà - Barcelona, Spain Susana Gomes Rodrigues - Bern, Switzerland Jordi Gracia - Barcelona, Spain Guohong Han - Xi'an, China Ziv J. Haskal - Charlotteville, USA Virginia Hernandez-Gea - Barcelona, Spain Jidong Jia - Beiing, China Jean Jacques Kiladjian - Paris, France Aleksander Krag - Odense, Denmark Vincenzo La Mura - Milan, Italy

Wim Laleman - Leuven, Belgium

Baveno II CONSENSUS WORKSHOP PERSONALIZED CARE IN PORTAL HYPERTENSION October 27-30, 2021

FACULTY

Sabela Lens - Barcelona, Spain

Xuefeng Luo - Chengdu, China

Mattias Mandorfer - Vienna, Austria

Sarwa Darwish Murad - Rotterdam, The Netherlands

Valerie Paradis - Clichy, France

David Patch - London, United Kingdom

Salvatore Piano - Padua, Italy

Massimo Pinzani - London, United Kingdom

Aurelie Plessier - Clichy, France

Massimo Primignani - Milan, Italy

Bogdan Procopet - Cluj-Napoca, Romania

Pierre Emmanuel Rautou - Paris, France

Thomas Reiberger - Vienna, Austria

Cristina Ripoll - Jena, Germany

Marika Rudler - Paris, France

Shiv K. Sarin - New Delhi, India

Filippo Schepis - Modena, Italy

Marco Senzolo - Padua, Italy

Vijay Shah - Rochester, USA

Akash Shukla - Mumbai, India

Puneeta Tandon - Edmonton, Canada

Luis Tellez - Madrid, Spain

Dominique Thabut - Paris, France

Maja Thiele - Odense, Denmark

Jonel Trebicka - Frankfurt, Germany

Dhiraj Tripathi - Birmingham, United Kingdom

Emmanouil A. Tsochatzis - London, United Kingdom

Laura Turco - Bologna, Italy

Fanny Turon - Barcelona, Spain

Dominique Valla - Clichy, France

Candid Villanueva - Barcelona, Spain

lan Wanless - Halifax, Canada

Hitoshi Yoshiji - Kashihara, Japan



HONORARY FACULTY

Flemming Bendtsen - Hvidovre (Denmark)

Norman Grace - Boston (USA)

Loren Laine - New Haven (USA)

Didier Lebrec - Clichy (France)

Carlo Merkel - Padua (Italy)

Manuela Merli - Rome (Italy) Richard Moreau - Clichy (France)

Frederik Nevens - Leuven (Belgium)

Markus Peck-Radosavljevic - Klagenfurt (Austria)

Francesco Salerno - Milan (Italy)

Tilman Sauerbruch - Bonn (Germany)

Benjamin Shneider - Houston (USA)

Jean Pierre Vinel - Toulouse (France)


Julio Vorobioff - Rosario (Argentina)

Baveno III consensus workshop

CONSENSUS VVORKSHOP <mark>PERSONALIZED CARE IN PORTAL HYPERTENSION</mark>

October 27-30, 2021





After Baveno VI, important advances have been made in understanding the pathophysiology of portal hypertension, as well as in developing new treatments and new strategies for the management of advanced cirrhosis and portal hypertension. For these reasons, we thought that the time had come to organize a seventh Baveno Workshop.

Baveno VII was planned for March 2020 and had to be cancelled a few weeks before the meeting was to be held. At that point in time, we had no sense how the pandemic would develop, and we first decided to postpone the meeting to October 2020. By the summer, the Executive Committee realized that this option was not realistic and had to postpone again to October 2021. Finally, due to the persisting uncertainties, the Executive Committee has recently decided to cancel the face-to-face meeting. Therefore, Baveno VII will be a complete virtual meeting to be held over 4 days (27th to 30th October). The meeting will be held over 4 to 4h30 per day, starting at 14h00 European time.


As for the previous editions, the aim of the Baveno VII Workshop is twofold: first, to review and put into perspective the changes in diagnostic and therapeutic strategies that have occurred in the past 5 years in the field of portal hypertension, Second, to continue the effort - which had begun in Baveno I more than thirty years ago - of producing updated definitions and guidelines aimed at improving the management of patients as well as the quality of our future studies. The Workshop will begin with a brief introduction, followed by three lectures, the first one on the new concept of risk stratification, the second one on clinical stages and ordinal outcomes in portal hypertension, and the third on lifestyle and genetic modifiers of progression of compensated advanced chronic liver disease.

BavenVII

CONSENSUS WORKSHOP <mark>PERSONALIZED CARE IN PORTAL HYPERTENSIO</mark>N

October 27-30, 2021





Roberto de Franchis

On behalf of the Baveno Cooperation Steering Committee

All times are CFT

WEDNESDAY OCTOBER 27 2021

14.00-14.30 Welcome and introduction R. de Franchis (Milan, Italy)

Tribute to the Baveno Legends

Tom Boyer Andy Burroughs Roberto Groszmann Luigi Pagliaro

14.30-15.15 INTRODUCTORY LECTURES

Chairpersons: J. Bosch (Bern, Switzerland), R. de Franchis (Milan, Italy), G. Garcia-Tsao (New Haven, USA)

LECTURE-1: New concept of risk stratification

J.G. Abraldes (Edmonton, Canada)

LECTURE-2: Clinical stages and ordinal outcomes in portal hypertension

G. D'Amico (Palermo, Italy)

LECTURE-3: Lifestyle and genetic modifiers of liver disease progression

A. Berzigotti (Bern, Switzerland)

15.15-15.30 Break



WEDNESDAY OCTOBER 27 2021

15.30-18.30 SESSION 1

EVALUATION AND RISK STRATIFICATION

15.30-16.15 PART 1: HVPG as a gold standard

Chairpersons: J.C. Garcia-Pagàn (Barcelona, Spain), Z. Haskal (Charlotteville, USA) Panelists: R. Gaba (Chicago, USA), H. Ferral (Evanston, USA), F. Schepis (Modena, Italy)

- Quality Metrics in HVPG and Porto-Systemic Pressure Gradient (PPG)
- Usefulness of HVPG in:
 - a. the diagnosis of CSPH in cirrhosis of different etiologies
 - assessing the response to vasoactive drugs for risk stratification of variceal (re-)bleeding
 - c. assessing the prognosis of patients with cirrhosis
 - d. clinical trials vs. proof-of-concept studies
- PPG in the setting of TIPS
- Consensus statements

16.15-16.30 Break

16.30-18.30 PART 2: Noninvasive tools for cACLD and portal hypertension

Chairpersons: A. Berzigotti (Bern, Switzerland), J. Genescà (Barcelona, Spain)
Panelists: J.G. Abraldes (Edmonton, Canada), J. Fallowfield (Edinburgh, United Kingdom),
M. Thiele (Odense, Denmark)

- cACLD and CSPH
- Detection of varices with noninvasive tools and screening endoscopy
- Use of noninvasive tools for prognosis in cirrhosis
- Spleen stiffness
- Emerging non-invasive markers: imaging, blood, and liver clearance tests
- Proposed consensus statements

End of the Day

THURSDAY OCTOBER 28 2021

14.00-14.30 Presentation of selected abstracts

14.30-17.30 SESSION 2

NEW SCENARIOS

14.30-15.15 PART 1: Progression and regression of cirrhosis Chairpersons: W. Laleman (Leuven), D. Patch (London)

LECTURE-4: PELS in progression. Can they regress?

I. Wanless (Halifax)

LECTURE-5: Fibrogenesis and regression of fibrosis

M. Pinzani (London)

LECTURE-6: Angiogenesis and progression of ACLD

V. Shah (Rochester)

15.15-15.30 Break

LECTURE-7: Drugs to modify liver fibrosis progression and regression (preclinical and clinical studies)

J. Gracia (Barcelona)

THURSDAY OCTOBER 28 2021

15.45-16.30 PART 2: Impact of etiological therapies in the course of cirrhosis

> Chairpersons: M. Mandorfer (Vienna, Austria), E. Tsochatzis (London, United Kingdom) Panelists: S. Francque (Antwerp, Belgium), J. Jia (Bejing, China), S. Lens (Barcelona, Spain), H. Yoshiji (Kashihara, Japan)

- Impact of etiological therapies on disease progression vs. regression in
 - Alcohol-related liver disease
 - Non-alcoholic fatty liver disease
 - Hepatitis B
 - Hepatitis C
- Presentation of recommendations for the management of cirrhosis after control of the primary etiological factor

16.30-16.45 Break

16.45-17.30 PART 3: Impact of non-etiological therapies in the course of cirrhosis

> Chairpersons: A. Albillos (Madrid, Spain), J. Trebicka (Frankfurt, Germany) Panelists: J. Bajaj (Richmond, USA), J. Gracia (Barcelona, Spain), A. Krag (Odense, Denmark), W. Laleman (Leuven, Belgium), V. Shah (Rochester, USA)

- Impact of drugs acting on the gut/microbiome
- Impact of statins and FXR/PPAR agonists in the treatment of patients with cirrhosis and portal hypertension
- Use of anticoagulants (LMWH, DOAC) and antiplatelet drugs (ASS) in the management of cirrhosis and portal hypertension
- Proposed consensus statements

17.30-17.45 Break



THURSDAY OCTOBER 28 2021

17.45-19.00 SESSION 3

CLINICAL SETTINGS

17.45-19.00 PART 1: Preventing (first) decompensation. Review of current evidence

Chairpersons: J. Bosch (Bern, Switzerland), C. Ripoll (Halle, Germany)
Panelists: R. Bañares (Madrid, Spain), V. Calvaruso (Palermo, Italy),
A. Dell'Era (Milan, Italy), S. Gomes Rodrigues (Bern, Switzerland),
D. Tripathi (Birmingham, United Kingdom), C. Villanueva (Barcelona, Spain)

- · Results of the questionnaire
- Definition of decompensation:
 - Systematic review of studies that evaluate the natural history of cirrhosis and their definition of decompensation
 - The role of jaundice, perihepatic ascites, MHE and bleeding due to portal hypertensive gastropathy in the definition of decompensation
 - Impact of the sole presence of infection and of sarcopenia (without other manifestations of decompensation) in the natural history of compensated cirrhosis
- Use of NSBB in prevention of (first) decompensation:
 - Specific evaluation of the effect of CSPH, reduction of HVPG and other predictive factors
 - Meta-analysis with individual patient data on the effects of Carvedilol in the prevention of first decompensation
- Proposed Consensus Statements: Prevention of first decompensation

End of the Day



FRIDAY OCTOBER 29 2021

14.00-14.30 Presentation of selected abstracts

14.30-15.30 INDUSTRY SPONSORED SYMPOSIUM

15.30-15.45 Break

15.45-18.15 SESSION 3

CLINICAL SETTINGS (CONTINUED)

15.45-16.45 PART 2: Acute variceal bleeding

Chairpersons: V. Hernández-Gea (Barcelona, Spain), D. Thabut (Paris, France)
Panelists: A. Cárdenas (Barcelona, Spain), A. Escorsell (Barcelona, Spain),
G. Han (Xi'an, China), X. Luo (Chengdu, China), D. Patch (London, United Kingdom),
B. Procopet (Cluj-Napoca, Romania), M. Rudler (Paris, France)

- Patient Risk stratification and prognostic factors
- Novelties in general management of Acute Variceal Bleeding (AVB)
- Endoscopic management: classic and new therapies
- Pre-emptive TIPS
- Management of refractory bleeding
- Proposed consensus statements

16.45-17.00 Break



FRIDAY OCTOBER 29 2021

17.00-18.15 PART 3: Preventing further decompensation. Review of current evidence

Chairpersons: G. Garcia-Tsao (New Haven, USA), T Reiberger (Vienna, Austria) Panelists: C. Bureau (Toulouse, France), G. D'Amico (Palermo, Italy), V. La Mura (Milan, Italy), S. Piano (Padua, Italy), P. Tandon (Edmonton, Canada), L. Turco (Bologna, Italy)

- Clinical concept of further decompensation: Outcomes and risk stratification
 - Mortality per type of initial event (ascites, variceal hemorrhage)
 - Further decompensation per type of initial event (VH or/and ascites)
- Prevention of further decompensation
 - Prevention of rebleeding and other further decompensating events
 - Should NSBB be used in patients with ascites for the prevention of further decompensation?
 - Readdress use of NSBB in patients with refractory ascites
 - TIPS redefining candidates
- Sarcopenia and frailty- Exploring its relationship with further decompensation
- Concept of cirrhosis re-compensation

End of the Day

SATURDAY OCTOBER 30 2021

14.00-15.00 INDUSTRY SPONSORED SYMPOSIUM

15.00-15.15 Break

SESSION 4

VASCULAR LIVER DISORDERS

15.15-16.30 PART 1. SPLANCHNIC VEIN THROMBOSIS

Chairpersons: S. Sarin (New Delhi, India), D. Valla (Clichy, France)
Panelists: A. Baiges (Barcelona, Spain), M. Barrufet (Barcelona, Spain),
J.J. Kiladjian (Paris, France), A. Plessier (Clichy, France), M. Primignani (Milan, Italy),
A. Shukla (Mumbai, India), F. Turon (Barcelona, Spain)

- Portal vein thrombosis. Anticoagulation vs Interventional radiology
- Staging of portal vein thrombosis. Recurrent thrombosis and prognostic factors for recurrence
- Myeloproliferative neoplasia and splanchnic vein thrombosis: Diagnosis and management

16.30-16.45 Break

SATURDAY OCTOBER 30 2021

SCIENTIFIC PROGRAMME

16.45-18.00 PART 2. OTHER ISSUES IN VASCULAR LIVER DISORDERS

Chairpersons: A. de Gottardi (Lugano, Switzerland), P.E. Rautou (Paris, France) Panelists: S. Murad (Rotterdam, The Netherlands), V. Paradis (Clichy, France), M. Senzolo (Padua, Italy), L. Tellez (Madrid, Spain)

- Anticoagulation (including DOACS) in cirrhotic and non-cirrhotic patients
- Portosinusoidal vascular disease/Idiopathic portal hypertension/noncirrhotic portal hypertension: refining diagnostic criteria including histological criteria
- Presentation of Consensus Statements (both part 1 and 2)

18.00-18.15 Break

18.15-18.45 DIGITAL BAVENO VII MEETING WRAP UP

R. de Franchis (Milan, Italy)
G. Garcia-Tsao (New Haven, USA)
J. Bosch (Bern, Switzerland)

End of the Workshop

BAVENO VII PEDIATRIC RESEARCH WORKSHOP

05* Rackground and Pationals for Investigation

SUNDAY OCTOBER 31, 2021

Primary Prophylaxis of Variceal Hemorrhage, Complexities in the Development of Evidence-Based Approaches in Pediatrics

15.00-17.05	Background and Nationale for investigation
15.00	Introduction and goals B. Shneider (Houston)
15.05	Morbidity and Mortality of First Variceal Hemorrhage J.P. Molleston (Indianapolis)
15.25	Experiences in Endoscopic Primary Prophylaxis M. Duché (Paris)
15.45	Rationale for Primary Prophylaxis in Adults R. de Franchis (<i>Milan</i>)
16.05	Complexity of a Randomized Clinical Trial in Pediatrics S. Ling (Toronto)
16.25	International Registries in Pediatric Liver Diseases - The PSC Experience M. Deneau (Salt Lake City)
16.45	Open Discussion - Q&A^
17.05-17.20	Break

BavenVII

CONSENSUS WORKSHOP
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021



- 17.20-19.30 Research Plan Discussion
 - 17.20 Introduction of a Pediatric Portal Hypertension Registry B. Shneider (Houston)
 - 17.30 Presentation of the First Variceal Hemorrhage Database
 J. Pimenta (Belo Horizonte)
 - 17.45 Presentation of the Primary Prophylaxis Database T. Grammatikopoulos (London)
 - 18.00 Primary and Pre-primary Prophylaxis of Variceal Hemorrhage with the MesoRex Bypass and a MesoRex Bypass Registry R. Superina (Chicago)
 - 18.15 Registry Discussion^
 - 19.00 Concluding Remarks
 J. Bosch[^] (Berne)
 - 19.15 Plans Forward
 B. Shneider ^ (Houston)
- * times CET ^ all talks are pre-recorded with the exception of the ones marked by ^ which will be as a panel discussion with on-line questions via a chat-type function

FACULTY

Jaime Bosch - Bern, Switzerland Roberto de Franchis - Milan, Italy Mark Deneau - Salt Lake City, USA Mathieu Duché - Paris, France

Tassos Grammatikopoulos - London, United Kingdom

Simon C. Ling - Toronto, Canada Jean P. Molleston - Indianapolis, USA Júlio R. Pimenta - Belo Horizonte, Brazil Benjamin L. Shneider - Houston, USA Riccardo Superina - Chicago, USA



CONSENSUS WORKSHOP
PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021





FRIDAY OCTOBER 29 2021

14.30-15.30 INDUSTRY SPONSORED SYMPOSIUM

CONTROLLED EXPANSION TIPS. WHERE ARE WE? Historic overview and a future outlook. More than 20 years of GORE® VIATORR® TIPS Endoprosthesis

Moderation: T. Reiberger (Vienna, Austria)

- 14.30 The history of the TIPS procedure.

 Experience with the GORE® VIATORR® TIPS Endoprosthesis

 J. Bosch (Bern, Switzerland)
- 14.45 Pre-emptive TIPS in patients with high risk acute variceal bleeding

 J.C. Garcia-Pagán (Barcelona, Spain)
- 15.00 The future of small TIPS
 J. Trebicka (Frankfurt, Germany)
- 15.15 Conclusion by the moderator and discussion
- 15.30 Closing

PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021





SATURDAY OCTOBER 30 2021

14.00-15.00 INDUSTRY SPONSORED SYMPOSIUM

EUS-guided portal pressure measurement: expanding the horizon in portal hypertension assessment

- 14.00 Welcome
 J.C. García-Pagán (Barcelona, Spain)
- 14.05 Portal hypertension assessment Future Potential W. Laleman (Leuven, Blegium)
- 14.25 EUS-guided portal pressure measurement Early clinical experience
 S. van der Merwe (Leuven, Belgium)
- 14.45 Q&A discussion
- 14.58-15.00 Close

CONSENSUS WORKSHOP PERSONALIZED CARE IN PORTAL HYPERTENSION

October 27-30, 2021





REGISTRATION FEE

(22% VAT included- VAT is quoted according the actual rate in force. All rices will updated in case of legal changes in the applicable rates)

EARLY BIRD REGISTRATION - till September 10, 2021		450,00
• FULL REGISTRATION - after September 10, 2021		550,00
PEDIATRIC RESEARCH WORKSHOP**		75,00
YOUNG INVESTIGATOR EARLY BIRD FEE* - till September 10, 2021	€	150,00
YOUNG INVESTIGATOR FULL REGISTRATION - after September 10, 2021	€	200,00
YOUNG INVESTIGATOR PEDIATRIC RESEARCH WORKSHOP**		25,00
YOUNG INVESTIGATOR * "EMERGING COUNTRIES" ***	€	100,00

- Young investigators must be under 35 years old and still in training at the time of the Workshop. Proof of age and training status is mandatory
- ** Registation in the Baveno VII Workshop is mandatory to register for the Pediatric Research Workshop
- *** Emerging Countries are those defined as low-income and lower-middle income economies as determined by the World Bank

(Source: World Bank, low-income and lower-middle income countries current 2020 fiscal year - http://data.worldbank.org/about/country-and-lending-groups)

The Registration fee includes:

- Admission to scientific sessions
- Ammission to the exhibition area
- Attendance Certificate

HOW TO REGISTER IN THE WORKSHOP

Registration can be made online through the **www.baveno7.com** website and paid by credit card. Registration for the Workshop must be forwarded within October 12, 2021.



WITH THE SUPPORT OF















